Walsh, Fiona (2007) Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities. Therapeutics and Clinical Risk Management, 3 (5). pp. 789-794. ISSN 1176-6336

Preview

Download (82kB) | Preview

Abstract

Doripenem is a new parental 1-β-methyl carbapenem which, unlike imipenem, does not require the addition of cilastatin on administration because of the protection afforded to doripenem by the 1-β-methyl component. It combines the in vitro activities of imipenem and ertapenem against gram-positive bacteria with the in vitro activity of meropenem against gram-negative bacteria. It has excellent bactericidal activity against Streptococcus pneumoniae. Carbapenem resistant mutants were selected with less frequency and lower minimum inhibitory concentrations (MICs) after exposure to doripenem than to imipenem or meropenem. High concentration levels of doripenem may be achieved in plasma. The half life of doripenem is higher than imipenem or meropenem. This new antibiotic has excellent in vitro activity and pharmacological properties. but how it may best be utilized still needs to be determined.

Item Type:	Article
Keywords:	MIC; mutant; MBC; pharmacokinetics; pharmacodynamics;
Academic Unit:	Faculty of Science and Engineering > Biology
Item ID:	12671
Depositing User:	Fiona Walsh
Date Deposited:	31 Mar 2020 12:51
Journal or Publication Title:	Therapeutics and Clinical Risk Management
Publisher:	Dove Medical Press Ltd.
Refereed:	Yes
URI:	Publisher
Use Licence:	This item is available under a Creative Commons Attribution Non Commercial Share Alike Licence (CC BY-NC-SA). Details of this licence are available here

Repository Staff Only(login required)

Item control page

Downloads

Origin of downloads